Epidemiology, anticoagulant treatment and risk of thromboembolism in patients with valvular atrial fibrillation: Results from Atrial Fibrillation in Turkey: Epidemiologic Registry (AFTER)

Basit Öğe Kaydı
dc.contributor.authorKaya, Hasan
dc.contributor.authorErtas, Faruk
dc.contributor.authorKaya, Zekeriya
dc.contributor.authorEren, Nihan Kahya
dc.contributor.authorYuksel, Murat
dc.contributor.authorKoroglu, Bayram
dc.contributor.authorKose, Nuri
dc.date.accessioned2024-04-24T17:27:56Z
dc.date.available2024-04-24T17:27:56Z
dc.date.issued2014
dc.departmentDicle Üniversitesien_US
dc.description.abstractBackground: The aim of this study was to perform a multicenter, prospective investigation regarding the epidemiology, the current effectiveness of therapeutic anticoagulation, and the risk of thromboembolism in patients with valvular atrial fibrillation (AF) based on the records of the Atrial Fibrillation in Turkey: Epidemiologic Registry (AFTER) study. Methods: Patients were selected from a total of 2,242 consecutive admissions that presented with AF diagnosed via electrocardiogram. Those diagnosed with non-valvular AF were excluded from the AFTER study population, which left 497 patients with valvular AF for analysis. Results: The etiology of valvular AF in patients was either attributed to rheumatic mitral valve stenosis (n = 217) or possessing a prosthetic heart valve (n = 280). Out of all the patients with valvular AF, 83.1% were taking warfarin for anticoagulation. Only 36.1% demonstrated a therapeutic international normalized ratio (INR), and among those patients it was found that 19.1% exhibited a labile INR. Multivariate analysis revealed that age was the only independent predictor of thromboembolic events in patients with valvular AF. Conclusions: Many valvular AF patients are not maintained at therapeutic INR levels, which poses a threat to patient health as they age and are at greater risk for thromboembolism.en_US
dc.identifier.doi10.5603/CJ.a2013.0085
dc.identifier.endpage162en_US
dc.identifier.issn1897-5593
dc.identifier.issn1898-018X
dc.identifier.issue2en_US
dc.identifier.pmid23799558
dc.identifier.scopus2-s2.0-84898621629
dc.identifier.scopusqualityQ2
dc.identifier.startpage158en_US
dc.identifier.urihttps://doi.org/10.5603/CJ.a2013.0085
dc.identifier.urihttps://hdl.handle.net/11468/20262
dc.identifier.volume21en_US
dc.identifier.wosWOS:000334851500008
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherVia Medicaen_US
dc.relation.ispartofCardiology Journal
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAtrial Fibrillationen_US
dc.subjectValvularen_US
dc.subjectPredictoren_US
dc.subjectAnticoagulant Treatmenten_US
dc.titleEpidemiology, anticoagulant treatment and risk of thromboembolism in patients with valvular atrial fibrillation: Results from Atrial Fibrillation in Turkey: Epidemiologic Registry (AFTER)en_US
dc.titleEpidemiology, anticoagulant treatment and risk of thromboembolism in patients with valvular atrial fibrillation: Results from Atrial Fibrillation in Turkey: Epidemiologic Registry (AFTER)
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu